Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM93 in Recurrent EGFR-mutated Glioblastoma
NCT04933422Phase 1Not yet recruiting
- Sponsor
- Crimson BioPharm
- Start
- Jan 2027
- Primary completion
- Jul 2029
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of cm93 in glioblastoma (GBM) (3 arms), sponsored by Crimson BioPharm. Primary endpoints: Dose-limiting toxicities at 28 days, Maximum tolerated dose at 28 days and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
cm93
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04933422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933422.